Peer-reviewed veterinary case report
Oral drug KPT-335 tested for lymphoma treatment in dogs
By Sadowski, Abbey R et al.·Published in BMC veterinary research·2018·Cummings School, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.
- Species:
- dog
Plain-English summary
Fifty-eight dogs with lymphoma, including both B-cell and T-cell types, were treated with a new oral medication called KPT-335 (verdinexor) to see how well it worked. The treatment showed a 37% success rate overall, with an impressive 71% response rate in dogs with T-cell lymphoma. Most dogs tolerated the medication well, though some experienced mild loss of appetite, which could be managed with supportive care like prednisone. This study suggests that KPT-335 could be a promising option for treating lymphoma in dogs, and further research is encouraged.
People also search for: dog lymphoma treatment options · KPT-335 for dogs · canine lymphoma symptoms · prednisone for dog appetite loss
Abstract
BACKGROUND: Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study. The objective of this phase II study was to expand upon the initial findings and assess the activity and safety in a larger population of dogs with lymphoma. RESULTS: Fifty-eight dogs with naïve or progressive B-cell and T-cell lymphoma were enrolled in this clinical trial. KPT-335 was administered orally in one of three dosing groups, based on the previously established biologically active dose of 1.5 mg/kg three times weekly. Treatment with single-agent, orally administered KPT-335 resulted in an objective response rate (ORR) of 37%, of which dogs with T-cell lymphoma had an ORR of 71%. KPT-335 was well tolerated in all dose groups with grade 1-2 anorexia being the most common adverse event. Anorexia was responsive to symptomatic and supportive medications, including prednisone. CONCLUSIONS: These data demonstrate that KPT-335 has biologic activity in canine lymphoma, and support continued evaluation of SINE compounds such as KPT-335 in combination with standard chemotherapeutics in canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30143046/